サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566976

ウロキナーゼ市場：タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Urokinase Market By Type (Urokinase Powder, Urokinase Solution) , By End User (Hospital, Clinics) : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
ウロキナーゼ市場：タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ウロキナーゼ市場

ウロキナーゼ市場は2023年に18億米ドルと評価され、2024～2033年にかけてCAGR 5.7%で成長し、2033年には31億米ドルに達すると予測されています。

ウロキナーゼは血栓溶解薬であり、体内で血栓溶解に必要な物質が生成されるのを助ける。化学的には、ウロキナーゼはセリンプロテアーゼであり、ウロキナーゼ型プラスミノーゲン活性化因子（uPA）としても知られています。この化合物は当初ヒトの尿から単離され、血液といくつかの組織の細胞外マトリックスに存在します。この薬剤は静脈内に注射され、厳重に医師の管理下で投与されます。肺塞栓症、急性心筋梗塞、深部静脈血栓症などの治療に使用されます。

高齢者人口の急激な増加やライフスタイルの著しい変化に起因する心血管障害の有病率の増加は、ウロキナーゼ市場の主要な促進要因です。さらに、製剤の改良とドラッグデリバリーシステムの進歩が、効率的な治療ソリューションとしてウロキナーゼの需要を押し上げています。現在、ウロキナーゼの治療領域の拡大が市場の動向となっており、原発性ネフローゼ症候群や結核性胸膜炎の治療にウロキナーゼが有効であることが証明されています。結核性胸膜炎の治療では、抗結核療法とウロキナーゼの併用効果が、単独治療よりも比較的優れています。ウロキナーゼの併用は、残存胸膜厚を減少させ、総胸水量を増加させ、肺機能を改善し、胸水吸収時間を短縮させる。原発性ネフローゼ症候群では、ウロキナーゼは静脈血栓塞栓症を予防し、軽度の出血イベントも併発します。

しかし、出血性合併症のリスクは依然として大きく、ウロキナーゼ市場の成長を抑制しています。さらに、最新の抗凝固療法や組織プラスミノーゲン活性化因子（tPA）などの代替療法が主流であることも、市場開拓に大きな課題をもたらしています。その一方で、製剤の改良に向けた絶え間ない研究開発努力は、副作用が少なく患者のコンプライアンスを向上させる改良型製剤として、市場拡大の新たな機会をもたらしています。例えば、プロウロキナーゼとして知られるウロキナーゼの新しい前駆体は、現在臨床試験中です。この不活性前駆体は、活性型ウロキナーゼに変換される際にフィブリン特異的な生理的特性が確実に関与し、薬剤の有効性を高めることが知られています。

セグメント別レビュー

ウロキナーゼ市場はタイプ、エンドユーザー、地域に区分されます。タイプ別では、市場はウロキナーゼ粉末とウロキナーゼ溶液に二分されます。エンドユーザー別では、病院とクリニックに分けられます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

タイプ別では、ウロキナーゼ溶液セグメントが2023年の市場を独占しました。

エンドユーザー別では、病院セグメントが2023年の最高株主でした。

地域別では、アジア太平洋で市場が急拡大しています。

本レポートのカスタマイズの可能性（追加費用とスケジュールが必要です。）

  • 規制ガイドライン
  • クライアントの関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 ウロキナーゼ市場：タイプ別

  • 市場概要
  • ウロキナーゼ粉末
  • ウロキナーゼ溶液

第5章 ウロキナーゼ市場：エンドユーザー別

  • 市場概要
  • 病院
  • クリニック

第6章 ウロキナーゼ市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のウロキナーゼ市場
    • カナダのウロキナーゼ市場
    • メキシコのウロキナーゼ市場
  • 欧州
    • 主要市場動向と機会
    • ドイツのウロキナーゼ市場
    • フランスのウロキナーゼ市場
    • 英国のウロキナーゼ市場
    • イタリアのウロキナーゼ市場
    • スペインのウロキナーゼ市場
    • その他の欧州のウロキナーゼ市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本のウロキナーゼ市場
    • 中国のウロキナーゼ市場
    • オーストラリアのウロキナーゼ市場
    • インドのウロキナーゼ市場
    • 韓国のウロキナーゼ市場
    • その他のアジア太平洋のウロキナーゼ市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのウロキナーゼ市場
    • サウジアラビアのウロキナーゼ市場
    • 南アフリカのウロキナーゼ市場
    • その他のラテンアメリカ・中東・アフリカのウロキナーゼ市場

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第8章 企業プロファイル

  • NDpharm
  • Wanhua Biochem
  • Jiangxi Haoran Bio-Pharma
  • Jiangsu Aidea Pharmaceutical
  • Techpool
  • Microbic Biosystems Inc
  • Livzon Pharmaceutical Group Inc.
  • Cadila Healthcare Limited
  • TAJ Pharmaceuticals Limited
  • Microbix Biosystems Inc
目次
Product Code: A324534

Urokinase Market

The urokinase market was valued at $1.8 billion in 2023 and is projected to reach $3.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.

Urokinase is a clot-busting drug which helps the body produce substances necessary to dissolve blood clots. Chemically, urokinase is a serine protease and is also known as urokinase-type plasminogen activator (uPA). The compound was initially isolated from human urine and is present in blood & extracellular matrix of several tissues. The drug is injected intravenously and is strictly administered under medical supervision. The drug is used to treat several conditions such as pulmonary embolism, acute myocardial infarction, and deep vein thrombosis.

Increase in the prevalence of cardiovascular disorders owing to exponentially growing elderly population and significantly changing lifestyle is a major driver of the urokinase market. In addition, improvements in formulation and advancements in drug delivery systems are boosting the demand for urokinase as an efficient treatment solution. Expansion of the treatment horizon of urokinase is currently trending in the market, with the drug proving to be beneficial for the treatment of primary nephrotic syndrome and tuberculous pleurisy. The combined effect of the drug and antituberculous therapy is comparatively better for the treatment of tuberculous pleurisy, than the therapy alone. The integration of urokinase decreases residual pleural thickness, increases total pleural effusion, improves pulmonary function, and reduces pleural effusion absorption time. In primary nephrotic syndrome, urokinase prevents venous thromboembolism, coupled with minor bleeding events.

However, the risk of bleeding complications remains significant in various individuals, thereby restraining the growth of the urokinase market. Moreover, the predominant usage of alternatives, including latest anticoagulant therapies and tissue plasminogen activator (tPA), is presenting significant challenges for the market development. On the contrary, constant R&D efforts toward the refinement of formulations are presenting novel opportunities for market expansion as these improved formulations exhibit less side effects and enhance the patient compliance. For instance, a fresh precursor of urokinase, known as pro-urokinase, is under clinical trials currently. This inactive precursor ensures the involvement of its fibrin-specific physiologic properties during conversion into active urokinase that are known to enhance the efficacy of the drug.

Segment Review

The urokinase market is segmented into type, end user, and region. On the basis of type, the market is bifurcated into urokinase powder and urokinase solution. As per end user, it is divided into hospital and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the urokinase solution segment dominated the market in 2023.

As per end user, the hospital segment was the highest shareholder in 2023.

Region wise, the market is witnessing rapid expansion in Asia-Pacific.

Competition Analysis

The leading players operating in the global urokinase market include NDpharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc, Livzon Pharmaceutical Group Inc., Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, and Microbix Biosystems Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Urokinase Powder
  • Urokinase Solution

By End User

  • Hospital
  • Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • NDpharm
    • Wanhua Biochem
    • Jiangxi Haoran Bio-Pharma
    • Jiangsu Aidea Pharmaceutical
    • Techpool
    • Microbic Biosystems Inc
    • Livzon Pharmaceutical Group Inc.
    • Cadila Healthcare Limited
    • TAJ Pharmaceuticals Limited
    • Microbix Biosystems Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: UROKINASE MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Urokinase Powder
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Urokinase Solution
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: UROKINASE MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospital
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: UROKINASE MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Urokinase Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Urokinase Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Urokinase Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Urokinase Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Urokinase Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Urokinase Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Urokinase Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Urokinase Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Urokinase Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Urokinase Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Urokinase Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Urokinase Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Urokinase Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Urokinase Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Urokinase Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Urokinase Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Urokinase Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Urokinase Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Urokinase Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. NDpharm
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Wanhua Biochem
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Jiangxi Haoran Bio-Pharma
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Jiangsu Aidea Pharmaceutical
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Techpool
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Microbic Biosystems Inc
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Livzon Pharmaceutical Group Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Cadila Healthcare Limited
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. TAJ Pharmaceuticals Limited
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Microbix Biosystems Inc
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments